alexa Pioglitazone Vs Voglibose On Glycemic Control Study In Type II Diabetes In Indian Population
ISSN: 2155-6156

Journal of Diabetes & Metabolism
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

5th World Congress on Diabetes & Metabolism
November 03-05, 2014 Embassy Suites Las Vegas, USA

Premanidhi Panda
Keynote: J Diabetes Metab
DOI: 10.4172/2155-6156.S1.025
Introduction: Diabetes mellitus, often simply referred to as diabetes?is a group of metabolic diseases in which a person has high blood sugar, either because the body does not produce enough insulin, or because cells do not respond to the insulin that is produced. Type 2 diabetes mellitus consists of an array of dysfunctions characterized by hyperglycemia and resulting from the combination of resistance to insulin action, inadequate insulin secretion, and excessive or inappropriate glucagons secretion. It is with both Micro vascular & macro vascular complications. Type II diabetes is a progressive disease. It requires two to three drug combinations produce good effects and less side effects. Therefore these two drugs taken into consideration like Pioglitazone and Voglibose. It shows good glycemic control FBS, 2hr PPBS & HbA1C and Cholesterol and Triglyceride. Particularly study has been seen whose Blood sugar was not controlled by Glimiperide and Metformin. Intent: Intent of the study done By Author from 2012 February to July 2012over a period of 6Months over 200 Cases Type ?II Diabetes shows tremendous result in reduction of blood sugar, Maintenance of Blood sugar very stable as compared to with Pioglitazone or voglibose who are under Uncontrolled blood sugar with Glimeperide and Metformin. It shows good glycemic control Constant maintenance of HBA1C 5. 8 to 6. 5 range. Reduction in Lipid Profile Serum Cholesterol , Serum Triglyceride, LDL& VLDL. Method:-Two randomised group within the age group 30-70Years of Type II either sex given Pioglitazone and Voglibose with the FBS> 130mg/dl, HbA1C between 7-10 selected at random. All the parameters like FBS, 2hr PPBS, HbA1c, Lipid profile cholesterol, Triglyceride, LDL & VLDL observed time to time. It was observed within 6months FBS, 2hr PPBS, HbA1c, Cholesterol , TG, LDL&VLDL was greatly effected with Pioglitazone than Voglibose. Non of the patient complaint anything with pioglitazone except weight gain. With Voglibose few patient shows Flatulence, abdominal distension, Increase in LFT. Conclusion:-In my study shows Pioglitazone has got more effective drug than Voglibose Without any side effect. Better control of FBS, 2hr PPBS, Lipid Profile. In my study shows Pioglitazone has got minimal sideeffects than voglibose. ****I HAVE GOT >40, 000 Diabetes Patients. More than 20, 000Patients are under Pioglitazone since 2009. . Even I had given my view to Govt of India not to banned Pioglitazone.
Premanidhi panda has completed his MBBS at the age of 24 years from Berhampur University, India and postdoctoral studies from Utkal university School of Medicine. He is the director of Dr Panda diabetes institute, India, a premier Diabetes hospital cum research centre, India. He has worked in Tisco hospital, india, benghazi medical(libya), medwin hospital with repute. He has been awarded as ?India?s best doctor award:-2013(Diabetes)? by medgate today survey.
image PDF   |   image HTML

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version